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Objective. Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma (KS)-associated herpesvirus, is involved in KS and other tumors, including multicentric Castleman's disease and primary effusion lymphoma. Rituximab (RTX) is currently used for the treatment of several autoimmune or inflammatory diseases and humoral organ transplant rejection. De novo HHV-8 tumors induced by RTX used for these indications have not been reported previously. This study was undertaken to evaluate de novo HHV-8 tumors induced by RTX.
Methods. In this retrospective study, we investigated the clinical, virologic, and pathologic features of 5 HIV-negative male patients with HHV-8 tumors induced by RTX therapy.
Results. Patients were all immunocompromised by previous treatments, which consisted of steroids and/or immunosuppressive agents, and received RTX for insufficient response, disease progression, or transplant rejection. They developed HHV-8 tumors a median of 4 months after beginning treatment with RTX (range 3-13 months). Four patients had at least 1 risk factor for HHV-8, including a high Fitzpatrick skin phototype (of >3) (n = 3) and homosexuality (n = 1). Four patients developed KS (all 4 had skin lesions and 2 had visceral involvement), and 1 patient developed a solid primary effusion lymphoma. RTX was discontinued in all patients, and immunosuppressants were reduced when feasible. After a median follow-up of 20 months, 2 patients died. Remission of KS was complete in 1 patient and partial in 1 patient, and 1 patient had progression.
Conclusion. Our findings indicate that patients who have a high skin phototype and are at risk of HHV-8 should be carefully screened for HHV-8 before RTX therapy. The safety of RTX, especially in nonlymphomatous disorders, should be carefully evaluated in patients at risk of HHV-8 tumors.
Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma (KS)-associated herpesvirus, is an oncogenic herpesvirus belonging to the Rhadinovirus genus of the gammaherpesvirinae subfamily. It was identified in 1994, in KS skin lesions from an AIDS patient (1) . HHV-8 is involved in the pathogenesis of 3 neoplastic disorders, including KS, primary effusion lymphoma, and multicentric Castleman's disease (2) . Rituximab (RTX) is a chimeric monoclonal antibody (Mabthera; Roche) that targets the B cell surface antigen CD20 and is currently approved for the treatment of non-Hodgkin's lymphoma, rheumatoid arthritis (RA), and antineutrophil cytoplasmic antibody-associated vasculitis (3) . It may also be used for the treatment of B cell lymphoproliferative disorders, including primary effusion lymphoma and multicentric Castleman's disease, and humoral heart transplant rejection.
In courses (4, 5) . Nonetheless, RTX has been reported to exacerbate KS in patients with HIV-associated multicentric Castleman's disease (6) . RTX-related KS has also been reported in a few HIV-negative patients with multicentric Castleman's disease (2,7-9). Our literature search indicates that RTX has never been suspected as an inducer of de novo HHV-8 tumor in patients without multicentric Castleman's disease or diffuse large B cell lymphoma, especially in patients with vasculitis and autoimmune diseases. In this study, we describe 5 HIV-negative male patients with HHV-8 tumors induced by RTX.
PATIENTS AND METHODS
Between December 2011 and June 2015, 988 patients received RTX infusions at our institution (La Piti e-Salpêtri ere University Hospital), in the dermatology unit and oncology, rheumatology, internal medicine, and hematology departments. Five HIV-negative men (mean age 54 years [range 44-71 years]) with histologically proven HHV-8 tumors were included retrospectively. All had received RTX treatment for various indications (autoimmune diseases, steroid-resistant nephropathy, humoral heart transplant rejection, and retinal vasculitis). All patients were HIV negative. HIV testing was performed at the time of diagnosis of an autoimmune/inflammatory disease and systematically at the time of KS diagnosis. These patients had previously been treated with immunosuppressive drugs and were treated with RTX due to an insufficient response to previous treatment, disease progression, or humoral transplant rejection. RTX was prescribed as 1 of 2 regimens depending on the practitioner's determination of clinical need: either 4 weekly infusions of 375 mg/m 2 each or 2 infusions of 1 gm each on days 0 and 15.
We collected and retrospectively analyzed the epidemiologic, clinical, biologic, and histologic data for each patient in accordance with the Declaration of Helsinki. In order to stage the clinical outcome, we used HHV-8 tumor progression, partial remission or complete remission, and death, as defined in the AIDS Clinical Trials Group Oncology Committee study (10) . The Fitzpatrick skin phototype was determined. The Fitzpatrick skin phototype scale comprises 6 types, where type 1 indicates pale white skin, blue or green eyes, and blond or red hair (always burns, does not tan), type 2 indicates fair skin and blue eyes (burns easily, tans poorly), type 3 indicates darker white skin (tans after initial burn), type 4 indicates light brown skin (burns minimally, tans easily), type 5 indicates brown skin (rarely burns, tans darkly easily), and type 6 indicates dark brown or black skin (never burns, always tans darkly).
RESULTS
Patient characteristics. Of the 5 patients treated with RTX, 4 patients developed KS with skin lesions and 1 patient developed a solid primary effusion lymphoma. HHV-8 tumors were diagnosed a median of 4 months after the first RTX infusion (range 3-13 months). The characteristics of the patients are reported in Table 1 , and the characteristics of the HHV-8 tumors are listed in Table 2 .
The patients with KS (all men) did not have HIV, but they all had at least 1 risk factor for KS: black or dark skin (Fitzpatrick skin phototype >3), homosexuality, or solid organ transplantation (11) . Furthermore, all patients were immunocompromised by previous treatments, including steroids, as indicated by the presence of lymphopenia. The skin manifestations were classic papulonodular lesions sparing the face, neck, and mucous membranes. Two patients had visceral KS involvement, associated with lymph node enlargement ( Table 2 ). The patient with a solid primary effusion lymphoma (patient 5) had no skin lesions. For all patients, diagnosis of HHV-8 tumor was confirmed by morphologic analysis and positive latency-associated nuclear antigen 1 immunostaining (for KS and primary effusion lymphoma) (Figure 1) . Three of 4 patients tested had positive findings on an indirect fluorescent antibody (IFA) serologic test for latent infection with HHV-8 before RTX infusion. At the time of HHV-8 tumor diagnosis, the same 3 patients had positive findings on an IFA serologic test for HHV-8. Of note, HHV-8 DNA blood viral loads were undetectable (<1 log copy/10 6 cells) for all patients with KS but detectable at 3.33 log copies/10 6 cells for the patient with a primary effusion lymphoma. The blood Epstein-Barr virus DNA and cytomegalovirus DNA viral loads at the time of HHV-8 tumor diagnosis were significantly elevated above laboratory value cutoffs for positivity in patient 5 and patient 2, respectively.
Apart from HHV-8 tumors induced by RTX, we observed KS in 3 patients without HIV (1 patient with cerebral vasculitis who had been treated with cyclophosphamide [CYC] and corticosteroids, 1 patient with systemic sarcoidosis who had been treated with CYC, and 1 patient with psoriatic arthritis who had been treated with methotrexate), and 9 KS in organ transplant recipients. All of the patients had dark or black skin phototypes, and none of them had been exposed to tumor necrosis factor (TNF) inhibitors, tocilizumab, or other biologic agents.
Outcomes in patients with RTX-induced HHV-8 tumors. Treatment of RTX-induced HHV-8 tumors consisted of discontinuation of RTX for all patients and reduction of immunosuppressants when feasible. Except for the patient with a solid primary effusion lymphoma, none of the patients initially needed a specific KS treatment. Due to KS progression, 1 patient received local radiotherapy and then chemotherapy (PEGylated liposomal doxorubicin hydrochloride) (Caelyx; Janssen-Cilag) (4 infusions of 20 mg/m 2 each every 21 days). HHV-8 tumor prognosis was poor: 2 of the 5 patients died (7 and 599 days after KS diagnosis, respectively) and 1 still has disease in progression. At a median follow-up of 20 Table 2 . production by these infected B cells. In contrast, a decrease in the number of CD4+ T cells is considered to be a major factor associated with KS and multicentric Castleman's disease, whatever the origin of this T celldependent immunosuppression. However, one study has shown that advanced KS was associated with a decrease in B lymphocyte count or function (12) . Humoral immunity against HHV-8 infection has been described with minimal data on the role of HHV-8-neutralizing antibodies (13) . HHV-8 reactivation, the principal oncogene mechanism for KS, is a complex process that involves a combination of both viral and cellular factors, including temporary or prolonged immune suppression, oxidative stress, inflammatory cytokines, hypoxia, and treatment with chromatin-modifying agents (14) .
Based on these observations in the literature, one can speculate that RTX-impairing B cell clusters might down-regulate specific HHV-8 antibody levels and permit the emergence of KS or primary effusion HHV-8 TUMORS INDUCED BY RITUXIMABlymphoma in a context of accumulated immunosuppression. In our study the involvement of RTX therapy was very likely, since the onset of KS or primary effusion lymphoma occurred a few months after the first infusion and no other immunosuppressive drug was added. In addition, 3 patients developed visceral KS or primary effusion lymphoma with life-threatening disease. RTX is known to be associated with a welltolerated safety profile. A long-term follow-up study in RA has confirmed a consistent safety profile for RTX over time up to 11 years of follow-up for 3,595 patients. The overall serious infection event rate was 3.76/100 patient-years, and serious opportunistic infections remained infrequent (15) . Even if these severe adverse events are rare, vigilance is needed, particularly for immunocompromised patients. We did not observe HHV-8 tumors after treatment with tocilizumab, TNF inhibitors, or other biologic agents. However, other immunosuppressive therapies, such as CYC, methotrexate, and corticosteroids, are prone to induce HHV-8 tumors in patients who are at risk.
In conclusion, physicians should screen patients for risk of KS (high phototype corresponding to dark skin) and perform pretreatment serologic testing for HHV-8 to avoid development of RTX-induced HHV-8 tumors. The safety of RTX, especially in nonlymphomatous disorders, such as autoimmune and systemic inflammatory diseases, needs to be carefully evaluated in patients at risk of HHV-8 tumors.
